Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) shares were down 3% on Friday . The company traded as low as $10.02 and last traded at $10.03. Approximately 45,890 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 245,620 shares. The stock had previously closed at $10.34.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the stock. Citigroup reiterated a "market outperform" rating on shares of Abivax in a report on Friday. JMP Securities set a $33.00 target price on Abivax in a report on Friday. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $31.00.
Get Our Latest Stock Report on Abivax
Abivax Price Performance
The company has a debt-to-equity ratio of 1.29, a current ratio of 1.25 and a quick ratio of 1.25. The company's fifty day simple moving average is $7.14 and its 200 day simple moving average is $6.80.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Woodline Partners LP increased its stake in Abivax by 319.5% during the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company's stock valued at $1,262,000 after purchasing an additional 153,788 shares in the last quarter. Octagon Capital Advisors LP bought a new stake in Abivax during the first quarter valued at approximately $7,688,000. Millennium Management LLC grew its position in Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company's stock valued at $6,171,000 after buying an additional 56,235 shares during the period. Allostery Investments LP grew its position in Abivax by 86.0% during the first quarter. Allostery Investments LP now owns 1,099,654 shares of the company's stock valued at $6,873,000 after buying an additional 508,401 shares during the period. Finally, ADAR1 Capital Management LLC boosted its position in shares of Abivax by 46.0% in the first quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company's stock worth $13,813,000 after purchasing an additional 696,626 shares during the period. 47.91% of the stock is currently owned by institutional investors.
About Abivax
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Further Reading
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
